Spectrum of activity:
|
Gram-positive
&
Gram-negative
|
Details of activity:
|
Triazolyl methylene penem that is a potent inhibitor of TEM and SHV type plasmid β-lactamases and also chromosomal Cephalosporinases of Enterobacter and Citrobacter. In combination with amoxycillin alowed activity against resistant (β-lactamase producing) bacteria such as Xanthamonas maltophilia, B. fragilis and more
|
Combined with other compounds:
|
No antimicrobial activity (2) so would need to have been paired with a β-lactam
|
Institute where first reported:
|
Beecham Pharmaceuticals (GSK, US)
|
Year first mentioned:
|
1987
|
Highest developmental phase:
|
Phase 1
|
Development status:
|
Inactive
|
Reason Dropped:
|
No antimicrobial activity (2)-by 2004 it was no longer in clinical development but may well have been discontinued earlier. Whilst it is a very potent inhibitor, it is quickly eliminated with an extrapolated terminal t½ of 31mins (1). BRL 42715, its development has been discontinued as a result of its low serum half-life (2)
|